Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity
Background Interferon (IFN) signalling pathways, a key element of the innate immune response, contribute to resistance to conventional chemotherapy, radiotherapy, and immunotherapy, and are often deregulated in cancer. The deubiquitylating enzyme USP18 is a major negative regulator of the IFN signal...
Päätekijät: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
Springer Nature
2020
|